全基因组和EXOME定序市场－全球产业规模、份额、趋势、机会和预测：按产品、工作流程、应用、最终用户、地区和竞争格局划分，2021-2031年

全球全基因组和EXOME定序市场预计将从 2025 年的 32.4 亿美元大幅成长至 2031 年的 69.3 亿美元，复合年增长率达 13.51%。

该市场涵盖专门用于对生物体整个DNA序列或蛋白质编码EXOME区域进行定序的技术和服务。其成长主要受高通量定序成本快速下降以及精准医疗迫切需求的推动，而精准医疗则需要广泛的基因组分析以实现个人化治疗。这些因素对于加速药物研发和提高复杂遗传疾病临床诊断的准确性至关重要。根据个人化医疗联盟预测，到2024年，个人化药物将占新核准治疗性分子实体的约38%，凸显了基因组数据在现代药物研发中的重要性。

然而，市场在管理和解读这些定序方法产生的大量资料集方面面临着许多挑战。对庞大的运算储存空间和专业生物资讯技能的需求，对许多医疗机构而言都是一个瓶颈。此外，关于资料隐私和病患基因记录伦理管理的严格监管要求，也增加了跨国资料交换的复杂性，并可能限制全球合作研究的扩充性。

市场驱动因素

定序成本和处理时间的显着降低是市场扩张的关键驱动力，这主要得益于高通量系统的引入。这些技术进步使实验室能够以远低于以往的成本分析海量基因组文库，从而使全基因测序从专门的研究工具转变为常规临床实践的一部分。这种营运模式的演变形成了一个良性循环：成本的降低推动了技术的普及，并促使製造商向诊断和研究中心提供先进的设备。例如，Illumina公司在2024年2月的财报中宣布，2023年全年共交付了352套NovaSeq X系统，显示业界正朝着更有效率、更经济的定序解决方案发展。

同时，政府主导的大规模基因组计画和不断增长的研究经费正显着推动对定序服务的需求。各国正投入大量资源进行人群层面的研究，旨在阐明遗传多样性，支持医疗服务提供者的日常工作流程，并促进建构精准医疗所需的庞大参考资料资料库。这一趋势在推动倡议快速数位化的大型公共卫生计划中尤其明显。根据美国国立卫生研究院 (NIH) 于 2024 年 2 月宣布的「我们所有人研究计画」(All of Us Research Program)，该计画已发布 245,388 个临床级全基因组序列资料集，旨在加速生物医学研究。这种海量数据的产生也延伸到了製药领域。 2024 年，再生元製药公司 (Regeneron Pharmaceuticals) 宣布其基因中心已完成第 200 万个EXOME序列测定，这充分展现了当前全球市场数据规模的惊人。

市场挑战

定序技术所产生的大量资料集的处理和解读难度极大，这成为全球全基因组和EXOME定序市场成长的主要障碍。高通量技术会产生Petabyte原始数据，而医疗机构往往会因为计算储存不足和生物资讯专业知识匮乏而面临严重的瓶颈。无法有效处理和分析这些基因组数据会延缓原始数据向临床应用的转化，增加营运成本并阻碍研究进展。因此，市场在扩展服务以满足日益增长的精准医疗需求方面面临着巨大挑战，重要的遗传资讯往往被困在孤立或整合度低的系统中。

数据管治凸显了这种营运障碍，并且仍然是整个生命科学产业面临的关键挑战。根据皮斯托亚联盟（Pistoia Alliance）的数据显示，54%的生命科学专业人士认为非结构化资料是2024年面临的主要挑战，48%的人认为缺乏元资料标准化阻碍了高效的资料存取和利用。这些数据表明，基因组数据的庞大体量和复杂性直接限制了药物研发和诊断技术进步的速度和效率，这限制了整个定序市场的成长前景。

市场趋势

从短读长定序到长读长定调查方法的转变调查方法改变市场模式。这项转变的驱动力在于，人们需要辨识结构变异并绘製复杂区域图谱，而这些区域往往被短读长定序平台所忽略。长读长定序技术在建构全面的参考基因组和阐明单倍型方面正变得日益重要，这显着提高了罕见疾病诊断的准确性。高通量长读长定序仪的商业性应用也推动了这项转变。根据Pacific Biosciences公司2024年2月发布的财报，该公司在2023财年共出货173套Revio定序系统，显示业界正大力推进这些先进技术的应用。

同时，随着全EXOME定序序 (WES) 被纳入临床肿瘤学，全面的肿瘤分析正逐渐成为标准流程。这项进展使肿瘤学家能够利用EXOME的切片检查来检测可治疗的突变，并比有限的标靶检测更有效地追踪治疗抗药性。 WES 可对体细胞突变进行全面分析，对于选择合适的标靶治疗和免疫疗法至关重要。 Guardant Health 的报告显示，2024 年 5 月，其临床检测量达到 46,900 例，比前一年增长 20%，这进一步印证了精准癌症治疗对广泛基因组数据的依赖性日益增强。

目录

第一章概述

第二章调查方法

第三章执行摘要

第四章：客户评价

5. 全球全基因组与EXOME定序市场展望

• 市场规模及预测
  • 按金额
• 市占率及预测
  • 按产品（套件、设备）
  • 依工作流程（全基因测序(WGS)、全EXOME定序(WES)）
  • 依应用领域（肿瘤学、微生物学、非侵入性产前检测 (NIPT)、其他）
  • 按最终用户（製药和生物技术公司、诊断实验室、医院和诊所、研究和学术机构、其他）
  • 按地区
  • 按公司（2025 年）
• 市场地图

6. 北美全基因组与EXOME定序市场展望

• 市场规模及预测
• 市占率及预测
• 北美洲：国家分析
  • 我们
  • 加拿大
  • 墨西哥

7. 欧洲全基因组与EXOME定序市场展望

• 市场规模及预测
• 市占率及预测
• 欧洲：国家分析
  • 德国
  • 法国
  • 英国
  • 义大利
  • 西班牙

8. 亚太地区全基因组与EXOME定序市场展望

• 市场规模及预测
• 市占率及预测
• 亚太地区：国家分析
  • 中国
  • 印度
  • 日本
  • 韩国
  • 澳洲

9. 中东和非洲全基因组和EXOME定序市场展望

• 市场规模及预测
• 市占率及预测
• 中东和非洲：国家分析
  • 沙乌地阿拉伯
  • 阿拉伯聯合大公国
  • 南非

10. 南美洲全基因组与EXOME定序市场展望

• 市场规模及预测
• 市占率及预测
• 南美洲：国家分析
  • 巴西
  • 哥伦比亚
  • 阿根廷

第十一章 市场动态

• 司机
• 任务

第十二章 市场趋势与发展

• 併购
• 产品发布
• 最新进展

13. 全球全基因组和EXOME定序市场：SWOT 分析

第十四章：波特五力分析

• 产业竞争
• 新进入者的可能性
• 供应商电力
• 顾客权力
• 替代品的威胁

第十五章 竞争格局

• Illumina
• Thermo Fisher Scientific
• BGI Genomics
• Oxford Nanopore Technologies
• Pacific Biosciences
• Agilent Technologies
• QIAGEN
• Roche
• PerkinElmer
• Macrogen

第十六章 策略建议

第十七章：关于研究公司及免责声明

The Global Whole Genome & Exome Sequencing Market is projected to expand significantly, rising from a valuation of USD 3.24 Billion in 2025 to USD 6.93 Billion by 2031, reflecting a compound annual growth rate of 13.51%. This market encompasses technologies and services dedicated to decoding the entire DNA sequence of an organism or its protein-coding exome segments. Growth is primarily underpinned by the rapid reduction in high-throughput sequencing costs and the urgent transition toward precision medicine, which demands extensive genomic profiling for individualized patient treatment. These elements are pivotal in expediting pharmaceutical research and enhancing the precision of clinical diagnostics for complex genetic disorders. According to the Personalized Medicine Coalition, it was reported in 2024 that personalized medicines represented roughly 38 percent of all newly authorized therapeutic molecular entities, underscoring the essential role of genomic data in contemporary drug development.

Nevertheless, the market faces a substantial obstacle in the form of managing and interpreting the immense datasets produced by these sequencing methodologies. The need for extensive computational storage and specialized bioinformatics skills creates a bottleneck for numerous healthcare facilities. Furthermore, strict regulatory requirements concerning data privacy and the ethical management of patient genetic records add complexity to the cross-border exchange of data, potentially constraining the global scalability of collaborative research efforts.

Market Driver

The marked reduction in sequencing expenses and processing times serves as a major engine for market expansion, fueled largely by the deployment of high-throughput systems. These technological advancements enable laboratories to analyze immense genomic libraries at costs significantly lower than in the past, transitioning whole genome sequencing from a specialized research tool to a component of routine clinical practice. This operational evolution establishes a feedback cycle wherein reduced costs drive adoption, encouraging manufacturers to supply advanced instrumentation to diagnostic and research centers. For instance, Illumina reported in its February 2024 financial results that it shipped 352 NovaSeq X units throughout 2023, indicating a robust industry trend toward these more efficient and affordable sequencing solutions.

Simultaneously, the growth of large-scale government genomic programs and research funding is notably boosting the demand for sequencing services. Nations are committing substantial resources to population-level studies aimed at comprehending genetic diversity, which supports continuous workflows for providers and builds the extensive reference databases required for precision medicine. This drive is highlighted by major public health projects that are rapidly digitizing biobanks. According to the National Institutes of Health's February 2024 release regarding the 'All of Us Research Program', the initiative released a dataset comprising 245,388 clinical-grade whole genome sequences to speed up biomedical inquiry. This massive data generation extends to the pharmaceutical sector as well; Regeneron Pharmaceuticals announced in 2024 that its genetics center had sequenced its two millionth exome, demonstrating the colossal volume of data currently defining the global market.

Market Challenge

The intricacies involved in handling and interpreting the vast datasets produced by sequencing technologies represent a major barrier to the growth of the Global Whole Genome & Exome Sequencing Market. As high-throughput technologies yield petabytes of raw data, healthcare institutions often face critical bottlenecks caused by inadequate computational storage and a shortage of bioinformatics professionals. This incapacity to effectively process and analyze genomic data slows the conversion of raw sequences into practical clinical findings, raising operational expenses and hindering research progress. Consequently, the market encounters considerable difficulty in expanding its services to satisfy the rising demand for precision medicine, as essential genetic insights frequently remain locked within isolated or poorly integrated infrastructures.

Highlighting this operational obstacle, data governance persists as a significant issue throughout the life sciences industry. According to the Pistoia Alliance, in 2024, 54 percent of life science experts cited unstructured data as a primary difficulty, while 48 percent noted that the absence of metadata standardization restricts their ability to access and use data efficiently. These figures demonstrate how the immense volume and complexity of genomic data directly impede the speed and effectiveness of drug discovery and diagnostic advancement, thereby constraining the overall growth prospects of the sequencing market.

Market Trends

The shift from short-read to long-read sequencing methodologies is transforming the market, motivated by the necessity to identify structural variants and map complex regions that short-read platforms often overlook. Long-read technologies are becoming increasingly vital for constructing comprehensive reference genomes and resolving phased haplotypes, which significantly improves diagnostic precision for rare diseases. This transition is supported by the commercial uptake of high-throughput long-read instruments. According to Pacific Biosciences' financial results released in February 2024, the company shipped 173 Revio sequencing systems during the fiscal year 2023, indicating a strong industry trend toward adopting these sophisticated technologies.

At the same time, the incorporation of Whole Exome Sequencing (WES) into clinical oncology is becoming a standard practice for thorough tumor profiling. This development enables oncologists to use exome-based biopsies to detect actionable mutations and track treatment resistance more efficiently than limited targeted panels. WES offers a comprehensive examination of somatic changes, which is essential for choosing suitable targeted therapies and immunotherapies. As evidence of this growing reliance on extensive genomic data for precision cancer care, Guardant Health reported in May 2024 that its clinical test volumes reached 46,900, marking a 20 percent year-over-year increase.

Key Market Players

• Illumina
• Thermo Fisher Scientific
• BGI Genomics
• Oxford Nanopore Technologies
• Pacific Biosciences
• Agilent Technologies
• QIAGEN
• Roche
• PerkinElmer
• Macrogen

Report Scope

In this report, the Global Whole Genome & Exome Sequencing Market has been segmented into the following categories, in addition to the industry trends which have also been detailed below:

Whole Genome & Exome Sequencing Market, By Product

• Kits
• Instruments

Whole Genome & Exome Sequencing Market, By Workflow

• Whole Genome Sequencing (WGS)
• Whole Exome Sequencing (WES)

Whole Genome & Exome Sequencing Market, By Application

• Oncology
• Microbial
• Non-Invasive Prenatal Testing (NIPT)
• Others

Whole Genome & Exome Sequencing Market, By End User

• Pharmaceutical and Biotechnology Companies
• Diagnostic Laboratories
• Hospitals and Clinics
• Research and Academic Institutes
• Others

Whole Genome & Exome Sequencing Market, By Region

• North America
  • United States
  • Canada
  • Mexico
• Europe
  • France
  • United Kingdom
  • Italy
  • Germany
  • Spain
• Asia Pacific
  • China
  • India
  • Japan
  • Australia
  • South Korea
• South America
  • Brazil
  • Argentina
  • Colombia
• Middle East & Africa
  • South Africa
  • Saudi Arabia
  • UAE

Competitive Landscape

Company Profiles: Detailed analysis of the major companies present in the Global Whole Genome & Exome Sequencing Market.

Available Customizations:

Global Whole Genome & Exome Sequencing Market report with the given market data, TechSci Research offers customizations according to a company's specific needs. The following customization options are available for the report:

Company Information

• Detailed analysis and profiling of additional market players (up to five).

Table of Contents

1. Product Overview

• 1.1. Market Definition
• 1.2. Scope of the Market
  • 1.2.1. Markets Covered
  • 1.2.2. Years Considered for Study
  • 1.2.3. Key Market Segmentations

2. Research Methodology

• 2.1. Objective of the Study
• 2.2. Baseline Methodology
• 2.3. Key Industry Partners
• 2.4. Major Association and Secondary Sources
• 2.5. Forecasting Methodology
• 2.6. Data Triangulation & Validation
• 2.7. Assumptions and Limitations

3. Executive Summary

• 3.1. Overview of the Market
• 3.2. Overview of Key Market Segmentations
• 3.3. Overview of Key Market Players
• 3.4. Overview of Key Regions/Countries
• 3.5. Overview of Market Drivers, Challenges, Trends

4. Voice of Customer

5. Global Whole Genome & Exome Sequencing Market Outlook

• 5.1. Market Size & Forecast
  • 5.1.1. By Value
• 5.2. Market Share & Forecast
  • 5.2.1. By Product (Kits, Instruments)
  • 5.2.2. By Workflow (Whole Genome Sequencing (WGS) Whole Exome Sequencing (WES))
  • 5.2.3. By Application (Oncology, Microbial, Non-Invasive Prenatal Testing (NIPT), Others)
  • 5.2.4. By End User (Pharmaceutical and Biotechnology Companies, Diagnostic Laboratories, Hospitals and Clinics, Research and Academic Institutes, Others)
  • 5.2.5. By Region
  • 5.2.6. By Company (2025)
• 5.3. Market Map

6. North America Whole Genome & Exome Sequencing Market Outlook

• 6.1. Market Size & Forecast
  • 6.1.1. By Value
• 6.2. Market Share & Forecast
  • 6.2.1. By Product
  • 6.2.2. By Workflow
  • 6.2.3. By Application
  • 6.2.4. By End User
  • 6.2.5. By Country
• 6.3. North America: Country Analysis
  • 6.3.1. United States Whole Genome & Exome Sequencing Market Outlook
    • 6.3.1.1. Market Size & Forecast
      • 6.3.1.1.1. By Value
    • 6.3.1.2. Market Share & Forecast
      • 6.3.1.2.1. By Product
      • 6.3.1.2.2. By Workflow
      • 6.3.1.2.3. By Application
      • 6.3.1.2.4. By End User
  • 6.3.2. Canada Whole Genome & Exome Sequencing Market Outlook
    • 6.3.2.1. Market Size & Forecast
      • 6.3.2.1.1. By Value
    • 6.3.2.2. Market Share & Forecast
      • 6.3.2.2.1. By Product
      • 6.3.2.2.2. By Workflow
      • 6.3.2.2.3. By Application
      • 6.3.2.2.4. By End User
  • 6.3.3. Mexico Whole Genome & Exome Sequencing Market Outlook
    • 6.3.3.1. Market Size & Forecast
      • 6.3.3.1.1. By Value
    • 6.3.3.2. Market Share & Forecast
      • 6.3.3.2.1. By Product
      • 6.3.3.2.2. By Workflow
      • 6.3.3.2.3. By Application
      • 6.3.3.2.4. By End User

7. Europe Whole Genome & Exome Sequencing Market Outlook

• 7.1. Market Size & Forecast
  • 7.1.1. By Value
• 7.2. Market Share & Forecast
  • 7.2.1. By Product
  • 7.2.2. By Workflow
  • 7.2.3. By Application
  • 7.2.4. By End User
  • 7.2.5. By Country
• 7.3. Europe: Country Analysis
  • 7.3.1. Germany Whole Genome & Exome Sequencing Market Outlook
    • 7.3.1.1. Market Size & Forecast
      • 7.3.1.1.1. By Value
    • 7.3.1.2. Market Share & Forecast
      • 7.3.1.2.1. By Product
      • 7.3.1.2.2. By Workflow
      • 7.3.1.2.3. By Application
      • 7.3.1.2.4. By End User
  • 7.3.2. France Whole Genome & Exome Sequencing Market Outlook
    • 7.3.2.1. Market Size & Forecast
      • 7.3.2.1.1. By Value
    • 7.3.2.2. Market Share & Forecast
      • 7.3.2.2.1. By Product
      • 7.3.2.2.2. By Workflow
      • 7.3.2.2.3. By Application
      • 7.3.2.2.4. By End User
  • 7.3.3. United Kingdom Whole Genome & Exome Sequencing Market Outlook
    • 7.3.3.1. Market Size & Forecast
      • 7.3.3.1.1. By Value
    • 7.3.3.2. Market Share & Forecast
      • 7.3.3.2.1. By Product
      • 7.3.3.2.2. By Workflow
      • 7.3.3.2.3. By Application
      • 7.3.3.2.4. By End User
  • 7.3.4. Italy Whole Genome & Exome Sequencing Market Outlook
    • 7.3.4.1. Market Size & Forecast
      • 7.3.4.1.1. By Value
    • 7.3.4.2. Market Share & Forecast
      • 7.3.4.2.1. By Product
      • 7.3.4.2.2. By Workflow
      • 7.3.4.2.3. By Application
      • 7.3.4.2.4. By End User
  • 7.3.5. Spain Whole Genome & Exome Sequencing Market Outlook
    • 7.3.5.1. Market Size & Forecast
      • 7.3.5.1.1. By Value
    • 7.3.5.2. Market Share & Forecast
      • 7.3.5.2.1. By Product
      • 7.3.5.2.2. By Workflow
      • 7.3.5.2.3. By Application
      • 7.3.5.2.4. By End User

8. Asia Pacific Whole Genome & Exome Sequencing Market Outlook

• 8.1. Market Size & Forecast
  • 8.1.1. By Value
• 8.2. Market Share & Forecast
  • 8.2.1. By Product
  • 8.2.2. By Workflow
  • 8.2.3. By Application
  • 8.2.4. By End User
  • 8.2.5. By Country
• 8.3. Asia Pacific: Country Analysis
  • 8.3.1. China Whole Genome & Exome Sequencing Market Outlook
    • 8.3.1.1. Market Size & Forecast
      • 8.3.1.1.1. By Value
    • 8.3.1.2. Market Share & Forecast
      • 8.3.1.2.1. By Product
      • 8.3.1.2.2. By Workflow
      • 8.3.1.2.3. By Application
      • 8.3.1.2.4. By End User
  • 8.3.2. India Whole Genome & Exome Sequencing Market Outlook
    • 8.3.2.1. Market Size & Forecast
      • 8.3.2.1.1. By Value
    • 8.3.2.2. Market Share & Forecast
      • 8.3.2.2.1. By Product
      • 8.3.2.2.2. By Workflow
      • 8.3.2.2.3. By Application
      • 8.3.2.2.4. By End User
  • 8.3.3. Japan Whole Genome & Exome Sequencing Market Outlook
    • 8.3.3.1. Market Size & Forecast
      • 8.3.3.1.1. By Value
    • 8.3.3.2. Market Share & Forecast
      • 8.3.3.2.1. By Product
      • 8.3.3.2.2. By Workflow
      • 8.3.3.2.3. By Application
      • 8.3.3.2.4. By End User
  • 8.3.4. South Korea Whole Genome & Exome Sequencing Market Outlook
    • 8.3.4.1. Market Size & Forecast
      • 8.3.4.1.1. By Value
    • 8.3.4.2. Market Share & Forecast
      • 8.3.4.2.1. By Product
      • 8.3.4.2.2. By Workflow
      • 8.3.4.2.3. By Application
      • 8.3.4.2.4. By End User
  • 8.3.5. Australia Whole Genome & Exome Sequencing Market Outlook
    • 8.3.5.1. Market Size & Forecast
      • 8.3.5.1.1. By Value
    • 8.3.5.2. Market Share & Forecast
      • 8.3.5.2.1. By Product
      • 8.3.5.2.2. By Workflow
      • 8.3.5.2.3. By Application
      • 8.3.5.2.4. By End User

9. Middle East & Africa Whole Genome & Exome Sequencing Market Outlook

• 9.1. Market Size & Forecast
  • 9.1.1. By Value
• 9.2. Market Share & Forecast
  • 9.2.1. By Product
  • 9.2.2. By Workflow
  • 9.2.3. By Application
  • 9.2.4. By End User
  • 9.2.5. By Country
• 9.3. Middle East & Africa: Country Analysis
  • 9.3.1. Saudi Arabia Whole Genome & Exome Sequencing Market Outlook
    • 9.3.1.1. Market Size & Forecast
      • 9.3.1.1.1. By Value
    • 9.3.1.2. Market Share & Forecast
      • 9.3.1.2.1. By Product
      • 9.3.1.2.2. By Workflow
      • 9.3.1.2.3. By Application
      • 9.3.1.2.4. By End User
  • 9.3.2. UAE Whole Genome & Exome Sequencing Market Outlook
    • 9.3.2.1. Market Size & Forecast
      • 9.3.2.1.1. By Value
    • 9.3.2.2. Market Share & Forecast
      • 9.3.2.2.1. By Product
      • 9.3.2.2.2. By Workflow
      • 9.3.2.2.3. By Application
      • 9.3.2.2.4. By End User
  • 9.3.3. South Africa Whole Genome & Exome Sequencing Market Outlook
    • 9.3.3.1. Market Size & Forecast
      • 9.3.3.1.1. By Value
    • 9.3.3.2. Market Share & Forecast
      • 9.3.3.2.1. By Product
      • 9.3.3.2.2. By Workflow
      • 9.3.3.2.3. By Application
      • 9.3.3.2.4. By End User

10. South America Whole Genome & Exome Sequencing Market Outlook

• 10.1. Market Size & Forecast
  • 10.1.1. By Value
• 10.2. Market Share & Forecast
  • 10.2.1. By Product
  • 10.2.2. By Workflow
  • 10.2.3. By Application
  • 10.2.4. By End User
  • 10.2.5. By Country
• 10.3. South America: Country Analysis
  • 10.3.1. Brazil Whole Genome & Exome Sequencing Market Outlook
    • 10.3.1.1. Market Size & Forecast
      • 10.3.1.1.1. By Value
    • 10.3.1.2. Market Share & Forecast
      • 10.3.1.2.1. By Product
      • 10.3.1.2.2. By Workflow
      • 10.3.1.2.3. By Application
      • 10.3.1.2.4. By End User
  • 10.3.2. Colombia Whole Genome & Exome Sequencing Market Outlook
    • 10.3.2.1. Market Size & Forecast
      • 10.3.2.1.1. By Value
    • 10.3.2.2. Market Share & Forecast
      • 10.3.2.2.1. By Product
      • 10.3.2.2.2. By Workflow
      • 10.3.2.2.3. By Application
      • 10.3.2.2.4. By End User
  • 10.3.3. Argentina Whole Genome & Exome Sequencing Market Outlook
    • 10.3.3.1. Market Size & Forecast
      • 10.3.3.1.1. By Value
    • 10.3.3.2. Market Share & Forecast
      • 10.3.3.2.1. By Product
      • 10.3.3.2.2. By Workflow
      • 10.3.3.2.3. By Application
      • 10.3.3.2.4. By End User

11. Market Dynamics

• 11.1. Drivers
• 11.2. Challenges

12. Market Trends & Developments

• 12.1. Merger & Acquisition (If Any)
• 12.2. Product Launches (If Any)
• 12.3. Recent Developments

13. Global Whole Genome & Exome Sequencing Market: SWOT Analysis

14. Porter's Five Forces Analysis

• 14.1. Competition in the Industry
• 14.2. Potential of New Entrants
• 14.3. Power of Suppliers
• 14.4. Power of Customers
• 14.5. Threat of Substitute Products

15. Competitive Landscape

• 15.1. Illumina
  • 15.1.1. Business Overview
  • 15.1.2. Products & Services
  • 15.1.3. Recent Developments
  • 15.1.4. Key Personnel
  • 15.1.5. SWOT Analysis
• 15.2. Thermo Fisher Scientific
• 15.3. BGI Genomics
• 15.4. Oxford Nanopore Technologies
• 15.5. Pacific Biosciences
• 15.6. Agilent Technologies
• 15.7. QIAGEN
• 15.8. Roche
• 15.9. PerkinElmer
• 15.10. Macrogen

16. Strategic Recommendations

17. About Us & Disclaimer